|
1
|
Manson JJ and Isenberg DA: The
pathogenesis of systemic lupus erythematosus. Neth J Med.
61:343–346. 2003.PubMed/NCBI
|
|
2
|
Mok CC and Lau CS: Pathogenesis of
systemic lupus erythematosus. J Clin Pathol. 56:481–490. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Birmingham DJ and Hebert LA: The
complement system in lupus nephritis. Semin Nephrol. 35:444–454.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cross J and Jayne D: Diagnosis and
treatment of kidney disease. Best Pract Res Clin Rheumatol.
19:785–798. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuste C, Gutierrez E, Sevillano AM,
Rubio-Navarro A, Amaro-Villalobos JM, Ortiz A, Egido J, Praga M and
Moreno JA: Pathogenesis of glomerular haematuria. World J Nephrol.
4:185–195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ortega LM, Schultz DR, Lenz O, Pardo V and
Contreras GN: Review: Lupus nephritis: Pathologic features,
epidemiology and a guide to therapeutic decisions. Lupus.
19:557–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karsh J, Klippel JH, Balow JE and Decker
JL: Mortality in lupus nephritis. Arthritis Rheum. 22:764–769.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reyes-Thomas J, Blanco I and Putterman C:
Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol.
40:138–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kopetschke K, Klocke J, Griessbach AS,
Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P and
Riemekasten G: The cellular signature of urinary immune cells in
lupus nephritis: New insights into potential biomarkers. Arthritis
Res Ther. 17:942015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crispin JC: A TWEAK in lupus nephritis.
Clin Immunol. 145:139–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sanz AB, Izquierdo MC, Sanchez-Niño MD,
Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C and Ortiz
Ap: TWEAK and the progression of renal disease: Clinical
translation. Nephrol Dial Transplant. 29 Suppl 1:i54–i62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rayego-Mateos S, Morgado-Pascual JL, Sanz
AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A
and Ruiz-Ortega M: TWEAK transactivation of the epidermal growth
factor receptor mediates renal inflammation. J Pathol. 231:480–494.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schwartz N, Su L, Burkly LC, Mackay M,
Aranow C, Kollaros M, Michaelson JS, Rovin B and Putterman C:
Urinary TWEAK and the activity of lupus nephritis. J Autoimmun.
27:242–250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schwartz N, Rubinstein T, Burkly LC,
Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W,
et al: Urinary TWEAK as a biomarker of lupus nephritis: A
multicenter cohort study. Arthritis Res Ther. 11:R1432009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hotta K, Sho M, Yamato I, Shimada K,
Harada H, Akahori T, Nakamura S, Konishi N, Yagita H, Nonomura K
and Nakajima Y: Direct targeting of fibroblast growth
factor-inducible 14 protein protects against renal ischemia
reperfusion injury. Kidney Int. 79:179–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Z, Burkly LC, Campbell S, Schwartz N,
Molano A, Choudhury A, Eisenberg RA, Michaelson JS and Putterman C:
TWEAK/Fn14 interactions are instrumental in the pathogenesis of
nephritis in the chronic graft-versus-host model of systemic lupus
erythematosus. J Immunol. 179:7949–7958. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Armstrong CL, Galisteo R, Brown SA and
Winkles JA: TWEAK activation of the non-canonical NF-κB signaling
pathway differentially regulates melanoma and prostate cancer cell
invasion. Oncotarget. 7:81474–81492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Michaelson JS, Wisniacki N, Burkly LC and
Putterman C: Role of TWEAK in lupus nephritis: A bench-to-bedside
review. J Autoimmun. 39:130–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Smith EL and Shmerling RH: The American
College of Rheumatology criteria for the classification of systemic
lupus erythematosus: Strengths, weaknesses and opportunities for
improvement. Lupus. 8:586–595. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mikdashi J and Nived O: Measuring disease
activity in adults with systemic lupus erythematosus: The
challenges of administrative burden and responsiveness to patient
concerns in clinical research. Arthritis Res Ther. 17:1832015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gladman DD, Ibañez D and Urowitz MB:
Systemic lupus erythematosus disease activity index 2002. J
Rheumatol. 29:288–291. 2000.
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stöger JL, Gijbels MJ, van der Velden S,
Manca M, van der Loos CM, Biessen EA, Daemen MJ, Lutgens E and de
Winther MP: Distribution of macrophage polarization markers in
human atherosclerosis. Atherosclerosis. 225:461–468. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sobecki M, Mrouj K, Camasses A, Parisis N,
Nicolas E, Llères D, Gerbe F, Prieto S, Krasinska L, David A, et
al: The cell proliferation antigen Ki-67 organises heterochromatin.
Elife. 5:e137222016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Christian F, Smith EL and Carmody RJ: The
regulation of NF-κB Subunits by phosphorylation. Cells. 5:E122016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wilhelmus S, Alpers CE, Cook HT, Ferrario
F, Fogo AB, Haas M, Joh K, Noël LH, Seshan SV, Bruijn JA and Bajema
IM: The revisited classification of GN in SLE at 10 Years: Time to
re-evaluate histopathologic lesions. J Am Soc Nephrol.
26:2938–2946. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Torres-Salido MT, Cortes-Hernandez J,
Vidal X, Pedrosa A, Vilardell-Tarres M and Ordi-Ros J: Neutrophil
gelatinase-associated lipocalin as a biomarker for lupus nephritis.
Nephrol Dial Transplant. 29:1740–1749. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wolf BJ, Spainhour JC, Arthur JM, Janech
MG, Petri M and Oates JC: Development of biomarker models to
predict outcomes in lupus nephritis. Arthritis Rheumatol.
68:1955–1963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chicheportiche Y, Bourdon PR, Xu H, Hsu
YM, Scott H, Hession C, Garcia I and Browning JL: TWEAK, a new
secreted ligand in the tumor necrosis factor family that weakly
induces apoptosis. J Biol Chem. 272:32401–32410. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fragoso-Loyo H, Atisha-Fregoso Y,
Nuñez-Alvarez CA and Llorente L: Utility of TWEAK to assess
neuropsychiatric disease activity in systemic lupus erhytematosus.
Lupus. 25:364–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu ZC, Zhou QL, Li XZ, Yang JH, Ao X,
Veeraragoo P and Zuo XX: Elevation of human tumor necrosis
factor-like weak inducer of apoptosis in peripheral blood
mononuclear cells is correlated with disease activity and lupus
nephritis in patients with systemic lupus erythematosus. Cytokine.
53:295–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang C, Chen LL, Pan HF, Leng RX, Qin WZ
and Ye DQ: Expression of human tumor necrosis factor-like weak
inducer of apoptosis in patients with systemic lupus erythematosus.
Clin Rheumatol. 31:335–339. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lech M and Anders HJ: The pathogenesis of
lupus nephritis. J Am Soc Nephrol. 24:1357–1366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iwata Y, Furuichi K, Kaneko S and Wada T:
The role of cytokine in the lupus nephritis. J Biomed Biotechnol.
2011:5948092011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feng X, Hao J, Liu Q, Yang L, Lv X, Zhang
Y, Xing L, Xu N and Liu S: HMGB1 mediates IFN-γ-induced cell
proliferation in MMC cells through regulation of cyclin D1/CDK4/p16
pathway. J Cell Biochem. 113:2009–2019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen HN, Wang DJ, Ren MY, Wang QL and Sui
SJ: TWEAK/Fn14 promotes the proliferation and collagen synthesis of
rat cardiac fibroblasts via the NF-κB pathway. Mol Biol Rep.
39:8231–8241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kwon OH, Kim JH, Kim SY and Kim YS:
TWEAK/Fn14 signaling mediates gastric cancer cell resistance to
5-fluorouracil via NF-κB activation. Int J Oncol. 44:583–590. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cherry EM, Lee DW, Jung JU and Sitcheran
R: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
promotes glioma cell invasion through induction of
NF-kappaB-inducing kinase (NIK) and noncanonical NF-κB signaling.
Mol Cancer. 14:92015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cameron MJ and Kelvin DJ: Cytokines and
chemokines-their receptors and their genes: An overview. Adv Exp
Med Biol. 520:8–32. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Turner MD, Nedjai B, Hurst T and
Pennington DJ: Cytokines and chemokines: At the crossroads of cell
signalling and inflammatory disease. Biochim Biophys Acta.
1843:2563–2582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chicheportiche Y, Chicheportiche R, Sizing
I, Thompson J, Benjamin CB, Ambrose C and Dayer JM: Proinflammatory
activity of TWEAK on human dermal fibroblasts and synoviocytes:
Blocking and enhancing effects of anti-TWEAK monoclonal antibodies.
Arthritis Res. 4:126–133. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y,
Kim DI, Park YB, Kwon BS, Park JE and Lee WH: TWEAK can induce
pro-inflammatory cytokines and matrix metalloproteinase-9 in
macrophages. Circ J. 68:396–399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Moore KW, de Waal Malefyt R, Coffman RL
and O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu
Rev Immunol. 19:683–765. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Iyer SS and Cheng G: Role of interleukin
10 transcriptional regulation in inflammation and autoimmune
disease. Crit Rev Immunol. 32:23–63. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sinuani I, Beberashvili I, Averbukh Z and
Sandbank J: Role of IL-10 in the progression of kidney disease.
World J Transplant. 3:91–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kitching AR, Katerelos M, Mudge SJ,
Tipping PG, Power DA and Holdsworth SR: Interleukin-10 inhibits
experimental mesangial proliferative glomerulonephritis. Clin Exp
Immunol. 128:36–43. 2002. View Article : Google Scholar : PubMed/NCBI
|
